|
Thursday, February 13, 2025, San Francisco, California, 7:00 PM – 9:00 PM Pacific Time (10:00 PM – 12:00 AM Eastern Time)
What Clinicians Want to Know: Addressing Current Questions Related to Novel Treatment Approaches for Urothelial Bladder Cancer and Prostate CancerA CME Symposium Held in Conjunction with the 2025 ASCO® Genitourinary Cancers Symposium
Location
San Francisco Marriott Marquis 780 Mission Street San Francisco, California Hotel Phone: (415) 896-1600 Program Schedule — Pacific Time 6:45 PM – 7:00 PM — Registration 7:00 PM – 9:00 PM — Educational Dinner Meeting Meeting Room Golden Gate Ballroom — Salon A (B2 Level) Faculty (Bladder Cancer)
Terence Friedlander, MD Professor of Medicine and Robert and Virginia O’Reilly Family Endowed Chair Chief, Division of Hematology/Oncology Zuckerberg San Francisco General Hospital Helen Diller Family Comprehensive Cancer Center University of California, San Francisco San Francisco, California Matthew D Galsky, MD Professor of Medicine Icahn School of Medicine at Mount Sinai Co-Leader, Bladder Cancer Center of Excellence Associate Director, Translational Research The Tisch Cancer Institute New York, New York
Faculty (Prostate Cancer)
Neeraj Agarwal, MD, FASCO Professor of Medicine Senior Director for Clinical Research Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research Director, Center of Investigational Therapeutics Director, Genitourinary Oncology Program Huntsman Cancer Institute University of Utah (NCI-CCC) Salt Lake City, Utah Andrew J Armstrong, MD, ScM Professor of Medicine, Surgery, Pharmacology and Cancer Biology Director of Research Duke Cancer Institute Center for Prostate and Urologic Cancers Divisions of Medical Oncology and Urology Duke University Durham, North Carolina Moderator Elisabeth I Heath, MD Chair, Department of Oncology Mayo Clinic Rochester, Minnesota This activity is supported by an educational grant from Astellas and Pfizer Inc.
Program Schedule — Pacific Time
6:45 PM – 7:00 PM — Registration 7:00 PM – 9:00 PM — Educational Dinner Meeting MODULE 1: Role of Antibody-Drug Conjugates (ADCs) in Front-Line Therapy for Metastatic Urothelial Bladder Cancer (mUBC) — Dr Friedlander
MODULE 2: Evidence-Based Use of ADCs for Relapsed/Refractory (R/R) mUBC — Dr Galsky
MODULE 3: Evolving Role of Treatment Intensification with Androgen Receptor (AR) Pathway Inhibitors for Nonmetastatic and Metastatic Prostate Cancer — Dr Armstrong
MODULE 4: Optimal Integration of PARP Inhibitors into Therapy for Prostate Cancer — Dr Agarwal
Target Audience
CME Credit Form FACULTY — Dr Agarwal has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities: Dr Armstrong — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Cytogen Corporation, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Curium, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc; Contracted Research: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Janssen Biotech Inc, Merck, Novartis, Pathos, Pfizer Inc. Dr Friedlander — Advisory Committees: Aadi Bioscience, AbbVie Inc, Adaptimmune, Aktis Oncology, Astellas, Bicycle Therapeutics, Bristol Myers Squibb, Gilead Sciences Inc, Merck, Pfizer Inc, Samsung Bioepis; Consulting Agreements: Astellas, EMD Serono Inc, Pfizer Inc; Contracted Research: Bicycle Therapeutics, Genentech, a member of the Roche Group, Johnson & Johnson Pharmaceuticals, Pfizer Inc; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics. Dr Galsky — Advisory Committees: AbbVie Inc, Aktis Oncology, Alligator Bioscience, Analog Devices Inc, Asieris Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bicycle Therapeutics, Bristol Myers Squibb, Curis Inc, Daiichi Sankyo Inc, Dragonfly Therapeutics, EMD Serono Inc, FUJIFILM Pharmaceuticals USA Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Janssen Biotech Inc, Merck, Numab Therapeutics AG, Pfizer Inc, Rappta Therapeutics, Seagen Inc, Silverback Therapeutics, UroGen Pharma, Veracyte Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Dendreon Pharmaceuticals Inc, Genentech, a member of the Roche Group, Merck, Novartis. MODERATOR — Dr Heath — Advisory/Consulting: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Sanofi; Honoraria/Paid Travel: Astellas, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Sanofi, Seagen Inc; Institutional Research Support: Amgen Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics Inc, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Corcept Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, F Hoffman-La Roche Ltd, Fortis Therapeutics, Gilead Sciences Inc, GSK, Harpoon Therapeutics, Infinity Pharmaceuticals Inc, iTeos Therapeutics, Janssen Biotech Inc, Merck, Mirati Therapeutics Inc, Modra Pharmaceuticals, MSD, Novartis, Oncolys BioPharma, Peloton Therapeutics Inc, a wholly-owned subsidiary of Merck & Co Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, POINT Biopharma, Seagen Inc; Steering Committees: Janssen Biotech Inc; Speakers Bureaus: Sanofi; Nonrelevant Financial Relationships: Calibr-Skaggs Institute for Innovative Medicines. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS This activity is supported by an educational grant from Astellas and Pfizer Inc. San Francisco Marriott Marquis
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of bladder and prostate cancers.
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited. NOTICE: Registration for this event is independent of registration for the 2025 ASCO Genitourinary Cancers Symposium. IN-PERSON Registration
Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 6:45 PM PT on Thursday, February 13th. If you are interested in attending, please visit our registration desk outside the Golden Gate Ballroom — Salon A (B2 Level) at the San Francisco Marriott Marquis hotel, 780 Mission Street, within walking distance (2 blocks) of the Moscone Convention Center. Please note: Seats will be offered on a first come, first served basis after prioritizing for clinicians in practice, and onsite registration does not guarantee participation in the meal service.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. NOTICE: Registration for this event is independent of registration for the 2025 Genitourinary Cancers Symposium. WEBCAST Registration for all professionals
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153. Not an official event of the 2025 ASCO® Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. |